COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies

Protocol No
MERCK-MK-7684A-004
Principal Investigator
Binod Dhakal
Phase
II
Summary
This trial is testing MK-7684 (also called vibostolimab) in combination with pembrolizumab (pembro) in people with cancer that affects the blood, bone marrow, and lymph nodes. This trial is being done to: * Test the safety of MK-7684A * See how the body tolerates MK-7684A * See how well MK-7684A works * Measure what happens as MK-7684A goes through the body * See if participants who get MK-7684A live longer * See if participants who get MK-7684A have a better quality of life
Description
Vibostolimab with Pembrolizumab in Relapsed or Refractory Hematological Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL